Table 1.
Baseline characteristics of the institutional AC cohort.
| Baseline characteristics | n=62 | |
|---|---|---|
| Age in years, median (IQR) | 41 | (34,0-48,3) |
| FIGO stage 1b, n (%) | 59 | (95) |
| FIGO stage 2a | 3 | (5) |
| Tumour size in mm, median (IQR) | 25 | (16,5-34,3) |
| Infiltration depth in mm, median (IQR) | 11 | (5,0-14,8) |
| LVSI, n (%)* | 14 | (29) |
| Parametrium tumour positive, n (%) | 1 | (2) |
| Pelvic lymph nodes tumour positive, n (%) | 10 | (16) |
| Resection margins tumour positive, n (%) | 13 | (21) |
| HPV positive, n (%) | 53 | (85) |
| Multiple infection, n (%)** | 3 | (5) |
| HPV 16, n (%) | 28 | (45) |
| HPV 18, n (%) | 23 | (37) |
| HPV 45, n (%) | 3 | (5) |
| Adjuvant radiation, n (%)*** | 20 | (32) |
| Adjuvant chemoradiation, n (%)*** | 3 | (5) |
| Follow-up in months, median (IQR) | 156 | (82-205) |
| Recurrent disease, n (%) | 13 | (21) |
| Locoregional recurrence, n (%) | 9 | (15) |
| Distant metastasis, n (%) | 4 | (6) |
| Overall death, n (%) | 20 | (32) |
| Disease specific death, n (%) | 12 | (19) |
Baseline characteristics. Baseline characteristics and clinicopathological parameters of all included cervical adenocarcinoma patients. *Of 14 cases the LVSI status was unknown. **Two cases were HPV16 and HPV18 positive, one case was HPV18 and HPV31 positive. ***Adjuvant treatment was proposed in case of tumour positive lymph nodes, tumour positive resection margins, tumour positive parametria, or in case of two or more of the following three unfavourable factors: tumour size >= 40mm, infiltration depth >=15mm, LVSI.
IQR, interquartile range; FIGO, International Federation of Gynaecology and Obstetrics; LVSI, lymph vascular space infiltration; HPV, human papillomavirus.